{"schema_version":"1.0","type":"article","title":"盤點整理，AI藥物開發走得如何了？","url":"https://drugnews.com.tw/articles/2026-06-12-ai-drug-discovery-pipeline-20260612.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-12-ai-drug-discovery-pipeline-20260612.md","lang":"zh-Hant","date":"2026-06-12","publish_at":"2026-06-12T10:30:00+08:00","updated_at":"2026-06-12","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","AI 製藥","臨床管線","BD","生技投資","藥物開發"],"summary":"AI 製藥已從概念走向臨床驗證。這篇盤點 Zasocitinib、GB-0895、Zovegalisib、REC-4881 等代表管線，拆解不同 AI 路線如何轉化成真正的藥物資產。","key_points":[],"facts":[],"sections":["見微知著 AI 製藥管線：模型很熱，但真正要看的是誰走進臨床","01｜Zasocitinib：用計算化學，把 TYK2 做到 Phase 3","02｜GB-0895：生成式 AI 抗體，開始挑戰長效化生物製劑","03｜Zovegalisib：AI 不只找分子，也能看見蛋白質動態裡的隱藏口袋","04｜REC-4881：AI 不一定要發明新藥，也可以幫老藥找到新用途","05｜這幾條管線共同說明：AI 製藥不是一種模式，而是四種不同能力","06｜AI 製藥的真正問題：不是模型能不能產生分子，而是分子能不能過人體","07｜Big Pharma 為什麼願意買單？因為 AI 有機會提高研發資本效率","結語｜AI 製藥不是風口，而是開始進入交卷期"],"references":[{"title":"[0]: 各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"YouTube","source":"","date":"","url":""},{"title":"Takeda today announced positive topline results for the two pivotal Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2","source":"","date":"","url":""},{"title":"www.takeda.com","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：盤點整理，AI藥物開發走得如何了？（圖 1）","url":"https://drugnews.com.tw/assets/articles/ai-drug-discovery-pipeline-20260612/dcard-01.webp"},{"alt":"Dcard 原圖：盤點整理，AI藥物開發走得如何了？（圖 2）","url":"https://drugnews.com.tw/assets/articles/ai-drug-discovery-pipeline-20260612/dcard-02.png"},{"alt":"Dcard 原圖：盤點整理，AI藥物開發走得如何了？（圖 3）","url":"https://drugnews.com.tw/assets/articles/ai-drug-discovery-pipeline-20260612/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/ai-drug-discovery-pipeline-20260612/cover-ai-drug-discovery.jpg","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-12）。盤點整理，AI藥物開發走得如何了？。https://drugnews.com.tw/articles/2026-06-12-ai-drug-discovery-pipeline-20260612.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-06-12-ai-drug-discovery-pipeline-20260612-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}